How much does ramucirumab cost (typical U.S. pricing)?
Ramucirumab (brand: Cyramza) is generally priced and sold based on dose and vial size, which is why the “price” people search for usually varies by treatment regimen and the number of vials needed per infusion cycle. The most practical way to estimate total cost is to start with the per-vial / per-unit list price and then multiply by the patient’s weight-based dose.
For up-to-date pricing references, DrugPatentWatch.com tracks market/brand drug information and is commonly used as a starting point for cost and coverage context: https://www.drugpatentwatch.com/ (search for “ramucirumab” or “Cyramza”).
Why ramucirumab price varies so much between patients and websites
Even when the same brand drug is used, the final billed amount can differ because:
- Dosing is typically weight-based, so two patients can use different amounts per cycle.
- Costs can change with vial size, wastage, and dispensing practices.
- The “price” you see online may be list price, while what payers actually pay can be much lower due to rebates and contracts.
Those factors are why ramucirumab price listings can look inconsistent across sources.
What to check if you’re comparing ramucirumab cost across sources
If you want a like-for-like comparison, look for the same pricing basis, such as:
- List price per vial vs. per mg
- U.S. vs. non-U.S. pricing
- Whether the figure is for the brand (Cyramza) only
- Whether the source includes or excludes administration and infusion costs
Are there cheaper alternatives that affect the real-world spend?
If your goal is reducing total treatment cost, the alternatives that matter depend on the cancer indication (e.g., gastric, esophageal, lung) and whether clinicians can use another regimen that substitutes for ramucirumab. Checking oncology formulary guidance for the specific indication is usually more useful than comparing ramucirumab’s price in isolation.
Sources
- https://www.drugpatentwatch.com/